Genzyme Corp. said it has received correspondence from the European Medicines Agency, the main drug regulatory agency for Europe, finding the Cambridge biotechnology company’s Allston plant “in general compliance with the principles and guidelines of good manufacturing practice.’’
European inspectors recommended the continued production of all drugs now made in Allston, the company said.
The inspectors in August identified several deficiencies at the plant, but the company has since addressed the problems.
Genzyme spokesman Bo Piela said inspectors from the US Food and Drug Administration have also been examining the plant.
The company temporarily suspended production at the Allston plant over the summer after a virus was found in a bioreactor used to make expensive drugs that treat rare genetic disorders.
